ClinicalTrials.gg
CompletedNCT01168310Updated May 27, 2013

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Fluticasone Propionate/Formoterol Fumarate and Fluticasone Propionate/Formoterol Fumarate in Chronic Obstructive Pulmonary Disease, sponsored by Dey. Completed at 23 sites in United States. Open to participants aged 40 Days and older. Per ClinicalTrials.gov, last updated 2013-05-27.

Sponsored by Dey (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
468
Allocation
Randomized
Ages
40 Days and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 4 under way, 1 of them phase 3. Fluticasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
15th of 59
468 · median 95
Started
2010
with 1 other
Phase 2
10 of 59
none open now
Registered
18th of 59
by date
Lead sponsor
3 of 59
Dey

Among the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 2 that started in 2010, is one of 10 in phase 2, and was the 18th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Days and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing fluticasone in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multi-dose, parallel group trial which will assess the pharmacodynamic response of fluticasone propionate and formoterol fumarate in subjects with COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Pulmonary, Obstructive, lungs, COPD
04

Who can participate

Ages eligible
40 Days and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the requirements of the study and provide written
  • A clinical diagnosis of
  • A current or prior history of at least 10-pack years of cigarette smoking
  • Women of (WOCBP) must have a negative pregnancy test at the screening visit and agree to avoid becoming pregnant for the duration of study

Exclusion criteria

Exclusion Criteria:

  • A clinical diagnosis of Asthma
  • Other significant disease than
  • Subjects who radiation or chemotherapy within the previous 12 months
  • Subjects who had any lung resection
  • greater than 0.460 seconds
  • History of illegal drug abuse or alcohol abuse within the past 5 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
468 participants (actual)

Study arms

  • Experimental
    1

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Experimental
    2

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Experimental
    3

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Experimental
    4

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Experimental
    5

    Drug: Fluticasone Propionate/Formoterol Fumarate

  • Active comparator
    6

    Drug: Formoterol Fumarate

  • Placebo comparator
    7

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in forced expiratory volume at one second (FEV1) measured in milliliters by spirometry to assess pharmacodynamic response of fluticasone propionate in combination with formoterol fumarate in subject with COPD

    Time frame: 12 Weeks

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: 12 Weeks

07

Study locations

23 sites
  • Investigative Site
    Phoenix, Arizona, United States
  • Investigative Site
    Fullerton, California, United States
  • Investigative Site
    San Diego, California, United States
  • Investigative Site
    Clearwater, Florida, United States
  • Investigative Site
    Deland, Florida, United States
  • Investigative Site
    Tamarac, Florida, United States
  • Investigative Site
    Lawrenceville, Georgia, United States
  • Investigative Site
    Coeur D'Alene, Idaho, United States
  • Investigative Site
    Madisonville, Kentucky, United States
  • Investigative Site
    Sunset, Louisiana, United States
  • Investigative Site
    Saint Louis, Missouri, United States
  • Investigative Site
    Charlotte, North Carolina, United States
  • Investigative Site
    Raleigh, North Carolina, United States
  • Investigative site
    Sylvania, Ohio, United States
  • Investigative Site
    Medford, Oregon, United States
  • Investigative Site
    Easley, South Carolina, United States
  • Investigative Site
    Gaffney, South Carolina, United States
  • Investigative Site
    Greenville, South Carolina, United States
  • Investigative Site
    Greer, South Carolina, United States
  • Investigative Site
    Spartanburg, South Carolina, United States
  • Invesigative Site
    Union, South Carolina, United States
  • Investigative Site
    San Antonio, Texas, United States
  • Investigative Site
    Spokane, Washington, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Aug 2010 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2010
First posted
Jul 23, 2010
Start
Aug 2010
Primary completionActual
Aug 2010
CompletionActual
Oct 2011
Results delay requested
May 10, 2013
Last update
May 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01168310
Lead sponsor
Dey
Responsible party
Sponsor
First posted
Jul 23, 2010
Start date
Aug 2010
Primary completion
Aug 2010
Completion
Oct 2011
Last update
May 27, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone · Formoterol

Start the discussion